Effect of photosensitizers photosens, photodithazine and hypericin on glioma cells and primary neuronal cultures : a comparative analysis by Mishchenko, Tatiana et al.
52   СТМ ∫ 2019 ∫ vol. 11 ∫ No.4 
 BIOTECHNOLOGIES 
Effect of Photosensitizers Photosens,  
Photodithazine and Hypericin on Glioma Сells  
and Primary Neuronal Cultures: a Comparative Analysis
DOI: 10.17691/stm2019.11.4.06 
Received August 2, 2019
Т.А. Mishchenko, PhD, Senior Researcher, Laboratory for Neuroprotection Methods Development,  
Center for Translational Technologies1; Senior Researcher, Molecular and Cellular Technologies Department,  
Institute of Fundamental Medicine2;
Е.V. Mitroshina, PhD, Associate Professor, Department of Neurotechnologies, Institute of Biology and Biomedicine1;  
Senior Researcher, Laboratory for Neuroprotection Methods Development, Center for Translational Technologies1;  
Senior Researcher, Molecular and Cellular Technologies Department, Institute of Fundamental Medicine2;
V.D. Turubanova, Master Student, Department of Neurotechnologies, Institute of Biology and Biomedicine1;  
Laboratory Assistant, Department of General Medical Genetics, Institute of Biology and Biomedicine1;
R. Alzeibak, PhD Student, Biophysics Department, Institute of Biology and Biomedicine1;
I.V. Balalaeva, PhD, Associate Professor, Biophysics Department, Institute of Biology and Biomedicine1;
М.V. Vedunova*, DSc, Leading Researcher, Institute of Biology and Biomedicine1;  
Director of Institute of Biology and Biomedicine1;
D.V. Krysko*, MD, PhD, Leading Researcher, Department of General Medical Genetics,  
Institute of Biology and Biomedicine1; Associate Professor, Head of Cell Death Investigation  
and Therapy Laboratory, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences3;  
Group Leader at CRIG4
1National Research Lobachevsky State University of Nizhni Novgorod, 23 Prospekt Gagarina, Nizhny Novgorod,  
 603950, Russia; 
2Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia; 
3Ghent University, Corneel Heymanslaan 10, Bldg 4B3, 9000, Ghent, Belgium; 
4Cancer Research Institute Ghent (CRIG), Corneel Heymanslaan 10, Bldg 4B3, 9000, Ghent, Belgium
The aim of the study was to compare the effect of photosensitizers photosens, photodithazine, and hypericin on primary brain cell 
cultures, and assess their toxic effect on tumor and normal nervous cells in order to choose the optimal photodynamic agent for glioma 
therapy.
Materials and Methods. The cytotoxicity of photosens (NIOPIK, Russia), photodithazine (Veta-grand, Russia) and hypericin (Merck 
KGaA; Sigma-Aldrich, Germany) was assessed on primary brain cell cultures obtained from C57BL/6 mice (gestation day 18). On day 14 of 
cultivation, the tested photosensitizers were added to a culture medium at concentrations of 0.1, 1, 10, 50, and 100 µM. Then the cultures 
were placed in a СО2-incubator in the dark. The viability of primary neuronal cultures was estimated on days 3 and 7 after photosensitizer 
application. Using confocal microscopy, we analyzed the rate of entry and subcellular localization of the tested agents in the primary 
neuronal cells. Statistical analysis was performed in SigmaPlot 11.0 (Systat Software Inc., USA) using ANOVA.
Results. We analyzed the absorption and fluorescence spectra of the tested photosensitizers. Photosens and photodithazine showed 
the presence of absorption maximum in short- and long-wave spectral ranges. Hypericin was characterized by a complex spectrum with 
many peaks in both blue-violet and orange-red spectral ranges. Cell viability analysis revealed that high concentrations of photosensitizers 
caused a pronounced toxic effect on nervous cells. The most marked effect was shown for photodithazine. Photosens exhibited the 
lowest accumulation rate in primary neuronal cells. Photosens and hypericin were found to have a high phototoxic effect on glioma, and 
demonstrated low dark toxicity for normal brain cells.
Conclusion. The photosensitizers hypericin and photosens are the least toxic for nervous tissue, though effectively penetrating in 
tumor cells. These properties enable to consider them as prospective photodynamic agents for clinic.
Key words: photosensitizers; photosens; photodithazine; hypericin; photodynamic therapy; neurooncology; cytotoxicity; primary 
neuronal cultures.
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The Effect of Photosensitizers on Brain Cells
Introduction
According to Central Brain Tumor Registry of the 
United States (CBTRUS) the frequency of diagnosed 
malignant and benign brain tumors is 10.71 cases per 
100,000 people under 39 years old, and 40.10 cases 
per 100,000 of population over 40 years of age [1, 
2]. Glioma is the most common brain tumor (75–
80% of primary malignancies) characterized by 
marked histological heterogeneity. Among these are 
astrocytomas (astrocytoma, anaplastic astrocytoma, 
glioblastoma multiforme), oligodendrogliomas and 
mixed gliomas. A distinctive feature of gliomas is 
rapid invasive growth, high proliferative activity, and 
intensive angiogenesis, which significantly reduce the 
effectiveness of therapy [3].
Contemporary anti-cancer therapy of brain tumors 
consists of a complex of procedures, including 
microsurgical tumor resection with distant postoperative 
radio- and chemotherapy [4]. Although gliomas have 
pronounced infiltrative growth and ability to involve 
functionally important parts of the brain to malignant 
process, conduction of radical surgical tumor eradication 
is not possible in most of the cases. Moreover, 96% of 
patients with maximum tumor resection have a relapse 
in a perifocal area within a short period of time [5, 6]. 
Blood-brain barrier (BBB) is also a significant challenge 
for anti-cancer therapy of brain tumors. Despite the fact 
that tumor growth is accompanied by BBB damage and 
an increase in its permeability, the use of drugs and their 
entry into tumor is impeded [7]. Screening of currently 
known cytostatic agents has revealed their low efficiency 
in brain tumor therapy, resulting in a limited list of 
officially approved drugs for malignant gliomas treatment 
[8, 9]. Thus, prognoses for patients with malignant glioma 
are still extremely unfavorable, even in case of using 
advanced treatment techniques. A lifetime after surgical 
tumor resection in population is about 10 months [10]. 
Low efficiency of traditional therapy of brain tumors 
and poor patient prognoses require improvement of the 
applied techniques, as well as a search for alternative 
approaches to treat this pathology.
Photodynamic therapy (PDT) is regarded as the 
most attractive strategy for effective adjuvant therapy 
of gliomas [11]. The method suggests the use of 
photosensitizers able to cross BBB and selectively 
accumulate in tumor [9, 12]. When exposed to visible 
light irradiation, an activated photosensitizer generates 
singlet oxygen and radical active oxygen species that 
have a direct cytotoxic effect on tumor cells causing their 
death, including an immunogenic pathway [13]. 
PDT also damages microvascular tumor environment 
due to vascular stagnation, thrombosis, and hemorrhage 
resulting in hypoxia and subsequent cell death [14, 15]. 
The efficiency of photodynamic damage effect depends 
on intracellular concentration of a photosensitizer, its 
localization in a cell, photochemical activity, and an 
irradiation dose.
Currently, the derivatives of hematoporphyrin (HpD), 
chlorin, phthalocyanine, as well as 5-aminolevulinic acid, 
the precursor of endogenous hematoporphyrin IX, are 
commonly used as photosensitizers in photodynamic 
therapy of brain tumors [16]. In European Union, 
hypericin (Sigma-Aldrich, Germany) is actively used 
photosensitizer [17], which has been shown to induce 
immunogenic cell death [18]. Photosens — sulfonated 
aluminium phthalocyanine (NIOPIK) [19] and a natural 
chlorin-based product — photodithazine (Veta-grand) 
are used for these purposes in Russia [20].
However, photodynamic agents may penetrate both 
a tumor and healthy nervous tissue, and there is still a 
question whether the concentrations of compounds, 
effective in photodynamic therapy, are toxic for non-
tumor nervous cells. The study of dark toxicity of 
photodynamic agents will enable to assess possible 
side effects on brain neuronal networks and choose the 
safest compounds.
The aim of the study was to compare the effect 
of photosensitizers photosens, photodithazine, and 
hypericin on primary brain cell cultures, and assess their 
toxic effect on tumor and normal nervous cells in order to 
choose the optimal agent for glioma therapy.
Materials and Methods
Photodynamic agents. The following photo-
sensitizers widely used currently in clinical practice have 
been analyzed (Figure 1):
Figure 1. Structures of the photosensitizers
Photosens Photodithazine Hypericin
SO3
–
nNa+
R=H, SO3
–
–SO3
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Photosens is a mixture of di-, tri-, and tetra-substituted 
fractions of sulfonated aluminium phthalocyanine with 
the number of sulfo group 3,4 (NIOPIK, Russia);
Photodithazine is bis-N-methylglucamine salt of 
chlorin e6 (Veta-grand, Russia);
Hypericin (4,5,7,4′,5′,7′-hexahydroxy-2,2′-dimethyl-
naphtho diatrone) (Merck KGaA; Sigma-Aldrich, 
Germany).
Primary brain cell cultures. Primary brain cell 
cultures were obtained from C57BL/6 murine embryos 
(gestation day 18). All procedures with animals were 
performed according to Rules for the Work using 
Experimental Animals (Russia, 2010), International 
Guiding Principles for Biomedical Research Involving 
Animals (CIOMS and ICLAS, 2012), as well as the ethic 
principles established by European Convention for the 
Protection of Vertebrate Animals used for Experimental 
and Other Scientific Purposes (Strasbourg, 2006). The 
study was also approved by the Bioethics Committee 
of National Research Lobachevsky State University of 
Nizhni Novgorod.
Isolation and long-term cultivation of dissociated 
brain cells were performed on coverslips (18×18 mm) 
according to the previously developed protocol [21]. 
Pregnant female mice were sacrificed by cervical 
vertebra dislocation. Then the embryos were removed 
from the uterus, and brain tissue was isolated followed 
by mechanical and 20-minute enzymatic treatment 
with 0.25% trypsin solution (Life Technologies, USA). 
Initial cell density was 4500 cells/cm2. Cell viability was 
supported in a СО2-incubator (Sheldon Manufacturing, 
USA). During cultivation, dissociated neuronal cells 
formed neuron-glial networks with specific spatial 
topology and functional activity. The key stages of 
neuron-glial networks formation were assessed using 
an inverted DMIL HC fluorescent microscope (Leica 
Biosystems, Germany).
Determination of dark toxicity of photosensitizers. 
In order to access the dark toxicity of photosensitizers 
for normal brain cells, the studied agents were added 
to a culture medium on day 14 of cultures development 
in vitro (DIV) at concentrations of 0.1, 1, 10, 50, and 
100 µM. Then, the cultures were placed in a CO2 
incubator and protected from light.
The viability of primary neuronal cultures were 
estimated on day 3 and 7 after compounds application 
using an inverted fluorescent microscope DMIL HC 
(Leica Biosystems, Germany) and specific fluorescent 
dyes — propidium iodide (Sigma-Aldrich, USA) and 
bis-benzimide (Sigma-Aldrich) in order to calculate 
the number of nuclei of dead cells relative to the total 
number of cells in a culture [21].
Accumulation dynamics of photosensitizers 
in normal brain cells. The features of penetration 
of photodynamic agents into the primary neuronal 
cells were assessed by confocal microscopy and a 
LSM-510 NLO system (Carl Zeiss, Germany). In order 
to visualize the cytoplasm of metabolically active cells 
a fluorescent calcium-sensitive dye Oregon Green 488 
BAPTA-1 АМ — OGB1 (Thermo Fisher Scientific, USA) 
was used. 
Fluorescence of OGB1 was excited at 488 nm by 
argon laser radiation, and emission was recorded in 
the range of 500 to 530 nm. The fluorescence of tested 
photosensitizers was excited at 633 nm by He-Ne-laser 
radiation, and recorded in the range of 650 to 715 nm. 
The concentration of the photosensitizers was 10 µM. 
The peculiarities of the agents accumulated in neuronal 
cells were assessed in 2 and 4 h after the start of 
incubation.
Analysis of subcellular distribution of 
photosensitizer in primary brain cell culture. To 
determine features of intracellular distribution of tested 
photosensitizers we performed a co-localization analysis 
using confocal microscopy and specific fluorescent dyes 
for different cellular organelles (Life Technologies, USA). 
The following parameters for fluorescence detection 
were used:
LysoTracker Green DND-26 is a lysosome marker; 
excitation wavelength: 488 nm; signal detection range is 
500–560 nm; fluorescence maximum is at 511 nm;
MitoTracker Green FM is a mitochondrial marker; 
excitation wavelength: 488 nm; signal detection range is 
500–560 nm; fluorescence maximum is at 516 nm;
ER-Tracker Green is an endoplasmic reticulum (ER) 
marker; excitation wavelength: 488 nm; signal detection 
range is 500–560 nm; fluorescence maximum is at 
511 nm.
On DIV 14, the culture medium was replaced by a 
serum-free medium containing the tested photosensitizer 
at concentration of 10 µM, and was incubated for 4 h. 
The fluorescence marker of lysosomes, mitochondria or 
ER at concentration of 0.5 µM was added to the culture 
medium 30 min before the end of incubation. Then the 
medium containing photosensitizer and organelle marker 
was replaced by a fresh serum-free medium.
On the obtained confocal images, the co-localization 
of a respective photodynamic agent and an organelle-
specific marker was confirmed by comparing signal 
distribution profiles in corresponding fluorescent 
channels.
Statistical data analysis. The obtained data are 
presented as a mean ± a standard error of the mean 
(М±SEM). The statistical analysis was performed using 
ANOVA implemented in Sigma Plot 11.0 software (Systat 
Software Inc., USA). Differences between groups were 
considered significant if the corresponding p-value was 
less than 0.05. 
Results
The main characteristics of the photosensitizers. 
First, we studied the absorption and fluorescent bands of 
the studied photodynamic agents (Table 1). Tetrapyrrol 
compounds — photosens and photodithazine — showed 
in spectra the presence of absorption maximum in short-
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wave (Soret band) and long-wave (Q-band) spectral 
regions. Photodithazine is characterized by a short-wave 
band dominating that is typical of chlorin dye group. 
A complex absorption spectrum with many maxima 
both in blue-violet and orange-red bands was found for 
hypericin.
Analysis of the dark toxicity of photosensitizers 
for normal neuronal cells. Next, we analyzed the dark 
toxicity effects of studied photosensitizers for primary 
neuronal cultures. It should be noted that nervous 
cells have certain patterns of long neuronal network 
degradation under stress; therefore, it is not enough 
to assess short-term toxic effects of the photodynamic 
agents. Thus, two main periods for toxicity assessment 
were chosen. Day 3 after a photosensitizer addition 
is a period when most cells exposed to a toxic effect 
die; and day 7 after exposure when a process of 
cell death ends, the cells have lost a great number of 
intercellular connections and received an internal signal 
for programmed death [22]. Moreover, it is necessary to 
assess the overall toxicity of the compounds in order to 
reveal the period of their adequate effect on the nervous 
system.
High concentrations of tested photosensitizers 
were found to have a marked toxic effect on nervous 
cells (Figure 2). The percentage of dead cells on day 
7 after photosensitizer addition at concentration of 
100 µM was exceeded 40% (photosens: 44.98±4.93%; 
hypericin: 63.8±4.12%; photodithazine: 45.62±5.67%). 
Low concentrations of photosens (0.1, 1, and 10 µM) 
had no marked toxic effect: the number of dead 
cells in the cultures was 8.04±0.72, 13.50±1.27, and 
8.56±0.75%, respectively. It should be noted that the 
viability of cultures on day 7 after addition of 0.1 and 
10 µM of photosens did not differ from the intact group 
(7.20±1.28%).
Hypericin at concentration of 10 µM exhibited a 
light cytotoxic effect. The percentage of nonviable 
cells exceeded the intact values and amounted to 
15.76±1.40%. Lower concentrations of hypericin had 
no marked cytoxic effect on primary neuronal cultures. 
The number of dead cells on day 7 after photosensitizer 
T a b l e  1
Spectral characteristics of the photosensitizers 
Photosensitizer λabs (nm)
ε 
(l·mol–1·cm–1) λem (nm)
Photosens 678* 30·10–4 690* 
Photodithazine 404*
643*
30·10–4
4.6·10–4 652* 
Hypericin 600** 30·10–4 604** 
N o t e : the used solvents: * water; ** DMSO (dimethyl 
sulfoxide). Here: λabs — absorption maximum; λem — 
fluorescence maximum.
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Figure 2. Dark toxicity assessment of commercial photosensitizers for primary brain cell 
cultures on day 3 and 7 after addition:
(а) photosens; (b) photodithazine; (c) hypericin; Y-axis — percentage of propidium iodide 
positive (dead) cells related to the total number of cells; * versus “Intact”, p<0.05, ANOVA 
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application was 9.50±1.23% (0.1 µM) and 
13.21±1.36% (1 µM).
Among the tested commercial 
photosensitizers, photoditazine has the 
most pronounced cytoxic effect. Even in low 
concentrations, a dose-dependent increase 
in the percentage of dead cells in cultures 
was observed by day 7 after its addition. The 
number of nonviable cells at application of 1 
and 10 µM of photoditazine was amounted to 
30.08±4.40 and 48.11±4.13%, respectively. Due 
to the identified high toxicity of photodithazine, 
additional concentrations of the photosensitizer 
were analyzed. It was shown that the use of 
0.66 µM was found to have average toxicity 
for primary neuronal cultures. The percentage 
of dead cells in the experimental group was 
19.63±1.62%.
Analysis of cellular uptake rate of 
the photosensitizers on primary brain 
cell cultures. In contrast to other tissues, 
the nervous cells have specific metabolic 
peculiarities. Neuroglia specializes in performing 
auxiliary functions for neurons, including 
trophic function, neurosecretion, and regulatory 
function, while neurons are characterized by 
decreased ability to uptake various compounds. 
The feature of tumor cells as a high metabolic 
rate, and often a glial nature, enables to 
select the compounds that fast accumulate in 
malignant cells and therefore exhibit minimal 
damaging effect on neurons.
Using confocal microscopy, we analyzed 
the uptake rate of the tested photodynamic 
agents for primary neuronal cultures. Hypericin 
and photodithazine were found to actively 
accumulate in neuron bodies and outgrowths 
as well as in glial cells 2 h after the start of 
incubation (Figure 3). The photosensitizers 
were observed in all cell types of primary 
neuronal cultures 4 h after their addition 
(Figure 4).
By contrast, the uptake rate of photosens 
by neurons was decreased. Photosens was 
detected only in glial elements of neuron-glial 
networks 2 h after application. The presence 
of the photosensitizer in neuron bodies and 
outgrowths was revealed after 4-hour incubation 
period.
Thus, among the tested photosensitizers, 
photosens showed the lowest accumulation rate 
in the nervous cells.
Intracellular distribution of 
photosensitizers in primary brain cell 
cultures. Apart from an uptake rate, 
intracellular localization of photodynamic agents 
is equally important aspect. This determines 
primary targets of light irradiation, molecular 
Figure 3. Representative confocal images of primary brain cell 
cultures 2 h after incubation with commercial photosensitizers:
(а) a fluorescent channel of calcium-sensitive dye Oregon Green 488 
BAPTA-1 АМ; (b) a fluorescent channel of a photosensitizer; (c) merge: 
overlay of the fluorescence channels; scale bars — 50 µm
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Figure 4. Representative confocal images of primary brain cell 
cultures 4 h after incubation with commercial photosensitizers:
(а) a fluorescent channel of calcium-sensitive dye Oregon Green 488 
BAPTA-1 АМ; (b) a fluorescent channel of a photosensitizer; (c) merge: 
overlay of the fluorescence channels; scale bars — 50 µm
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Figure 5. Analysis of intracellular 
localization of commercial photo-
sensitizers in primary brain cell 
cultures
Primary brain cell cultures were pre-
incubated with a photodynamic agent 
at concentration of 10 µM in 2 h. Then 
the primary neuronal cultures were 
stained with the following organelle 
dyes: LysoTracker Green DND-26 for 
lysosomes; MitoTracker Green FM 
for mitochondria; ER-Tracker Green 
for endoplasmatic reticulum (ER). 
Scale bars — 50 µm. In graphs: 
fluorescent signal profiles in the 
area of overlay of the fluorescence 
channels (white arrows on confocal 
images). Ifl — fluorescence intensity; 
D — the distance along the arrow
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mechanisms of a response and an immunogenic nature 
of cell death [23, 24].
In this regard, we studied a series of confocal images 
of primary brain cell cultures registered 2 h after the 
incubation with tested compounds. Co-localization 
of a photosensitizer fluorescent signal and a signal 
of dyes specifically staining such cellular organelles 
as lysosomes, ER, and mitochondria (Figure 5) was 
analyzed.
It was shown that photosens is mostly accumulated 
in the ER, and partially in lysosomes. Other two 
photosensitizers were found to locate in ER only.
A comparative analysis of glioma cells and primary 
neuronal cultures death induced by photodynamic 
treatment. In order to choose optimal photodynamic 
agents and select their concentrations exhibited both 
minimal dark toxicity for normal brain cells and a 
pronounced therapeutic effect in PDT, we performed 
a comparative analysis of the effect of photosensitizers 
at pre-established concentrations of IC50 for murine 
glioma GL261 cells (light dose of 20 J/cm2) on non-PDT 
treated primary brain cell cultures. Glioma GL261 cells 
were exposed to irradiation using a LED light source at a 
power of density 20 mW/cm2 (λex 630 nm) during 16 min 
40 s. For analysis, we used a cytotoxicity score according 
to ISO 10993-5-2009 (Table 2).
Study on photosensitizer concentrations enables 
to reveal the compounds, that may have potentially 
high phototoxic effect on glioma cells, but are low-toxic 
for nervous system cells, even under their long-term 
circulation in cerebrospinal fluid and intercellular space. 
Based on our results, hypericin and photosens can be 
definitely referred to this group (Table 3).
Discussion
Glioma therapy is currently an unresolved issue for 
global health care. Rapid course of the disease, high 
malignancy grade, and the shortest life expectancy 
make this pathology extremely difficult to treat and 
achieve persistent remission. A number of morphological 
characteristics of glioma, primarily, active migration 
of tumor cells to normal brain tissue increase risks of 
metastasis [3, 25, 26].
In case of adjuvant photodynamic therapy, it should 
take into consideration the effect of any pharmacological 
agents, including photosensitizers, on normal nervous 
cells. Brain neurons have certain metabolic peculiarities 
making them extremely sensitive to a toxic load. 
Differentiated neurons have a limited set of antioxidant 
enzymes incapable for division and regeneration, 
therefore, the loss of most functionally active 
connections lead to their death [27, 28].
In the present study, we have analyzed a toxic 
effect of some commercial photosensitizers on normal 
brain cells. The dark toxicity assessment of the tested 
compounds suggests that photodithazine has a marked 
toxic effect even in the absence of photo-induced cell 
death.
The data on uptake rate of the photosensitizers in brain 
cells and the agent distribution between neurons and 
astrocytes are of special interest. Photoinduction time 
calculation and the development of active detoxication 
measures can be a key to a novel therapeutic strategy 
based on photodynamic agents. Glioma has a higher 
metabolic rate compared to non-tumor cells [29, 30] and 
can accumulate photosensitizers faster than nervous 
system cells. Therefore, it is reasonable to suggest that 
a photodynamic agent can have minimal side effects 
for normal cells if its internalization rate in neurons 
is minimal, the rate being rather high for tumor cells. 
Among the studied compounds it is photosens.
Moreover, we analyzed the features of subcellular 
localization of the photosensitizers in primary brain cell 
cultures. The peculiarity of photosens that we have 
revealed is its localization not only in ER, but partially 
in lysosomes. In addition, photosens is characterized 
by vesicular localization in tumor cells. Photosens being 
a weak base due to nitrogen atoms of tetrapyrrol ring 
easily penetrates a lysosomal membrane, and remains 
in these organelles after dissociation under low pH [31]. 
It should be assumed that photosens redistribution 
between organelles will reduce the risk of normal cells 
death under photodynamic treatment [31–33].
In recent years, there have been intensive studies 
of molecular mechanisms of action of the compounds 
capable of providing cytotoxic effect, and also activate 
an anti-tumor immune response. If tumor cells die by an 
immunogenic pathway, then there occurs the secretion 
of damage-associated molecular patterns (DAMPs) [13, 
34]. DAMPs emission, in turn, leads to the induction 
of a strong Т-cell anti-tumor immune response, which 
T a b l e  3
Comparative assessment of cytotoxicity  
of the photosensitizers for glioma GL261 cells  
and primary neuronal cultures
Compounds
IC50 for glioma  
GL261 cells, µM 
(a light dose  
of 20 J/cm2)
Dark cytotoxicity  
for the primary neuronal 
cultures in the area of IC50  
of glioma GL261 cells
Photodithazin 0.8 [0.67; 0.92] 3 — severe cytotoxicity
Photosens 0.96 [0.79; 1.18] 0 — non-toxic
Hypericin 0.015 [0.013; 0.017] 0 — non-toxic
T a b l e  2
Cytotoxicity score according to the ISO 10993-5-2009
Cytotoxicity (points) Number of dead cells  in culture (%)
Interpretation  
of cytotoxicity 
0 0–10 Non-toxic  
1 10–20 Light
2 20–30 Average 
3 Over 30 Significant
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targets tumor cells remained after surgical resection 
and resistant to chemotherapy [34–36]. Previous studies 
have demonstrated an ability to induce immunogenic cell 
death through hypericin-based photodynamic therapy 
[33]. Since all the photosensitizers analyzed in this study 
accumulate in endoplasmic reticulum, they potentially 
have an ability to induce an ER stress by immunogenic 
pathway [13]. Therefore, further studies on capabilities of 
photodynamic agents to induce immunogenic cell death 
will enable to determine the most prospective agents for 
glioma therapy.
Conclusion 
This work allowed us to specify the photosensitizers 
which have low toxic effects on normal brain cells, and 
therefore, can be used in practice for photodynamic 
glioma therapy. The established property of both normal 
and also tumor glial cells to quickly accumulate all tested 
photosensitizers can be used in the development of new 
therapeutic strategy. Hypericin and photosens showed 
the lowest toxicity for normal nervous tissue, and 
effectively penetrate tumor cells.
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